What is Eli Lilly's SG&A?

Eli Lilly (LLY) reported SG&A of $2.93B in Q1 2026.

How has Eli Lilly's SG&A changed year-over-year?

Eli Lilly's SG&A increased by 18.9% year-over-year, from $2.47B to $2.93B.

What is the long-term trend for Eli Lilly's SG&A?

Over 4 years (2021 to 2025), Eli Lilly's SG&A has grown at a 14.6% compound annual growth rate (CAGR), from $6.43B to $11.09B.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Eli Lilly LLY SG&A

SG&A at other companies

PfizerPFE

$2.96B-2.3%

AmgenAMGN

$1.6B-5.0%

Cardinal HealthCAH

$1.54B+17.3%

BiogenBIIB

$607.3M+6.1%

MannkindMNKD

$54.09M+116%

McKessonMCK

$1.8B-9.1%

Segments

By segment

See full

Reportable Segment$2.93B+18.9%

Other financials

Income statement

See full

Revenue$19.8B+55.5%

Gross profit$16.2B+54.4%

Net income$7.4B+168%

EPS (diluted)$8.26+170%

Balance sheet

See full

Cash & equivalents$5.3B+70.8%

Total debt$43.4B+12.6%

Total equity$31.2B+97.9%

Total assets$116.58B+30.4%

Cash flow

See full

Operating cash flow$5.3B+220%

CapEx$2.3B+54.0%

Free cash flow$3.0B+1,828%

Valuation

See full

Market cap$1.01T+46.9%

Enterprise value$1.04T+44.9%

P/E39.8×-21.9×

P/S13.9×-0.1×

Profitability

See full

Gross margin82.8%+1.1pp

Net margin35%+12.3pp

FCF margin16.4%+8.7pp

Returns & leverage

See full

Return on equity107.6%+29.9pp

Debt / equity1.4×-1.1×

Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eli Lilly's SG&A?: Eli Lilly (LLY) reported SG&A of $2.93B in Q1 2026.
How has Eli Lilly's SG&A changed year-over-year?: Eli Lilly's SG&A increased by 18.9% year-over-year, from $2.47B to $2.93B.
What is the long-term trend for Eli Lilly's SG&A?: Over 4 years (2021 to 2025), Eli Lilly's SG&A has grown at a 14.6% compound annual growth rate (CAGR), from $6.43B to $11.09B.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.